The DNA synthesis company has poured money into a rapid business expansion at the expense of profitability and operating cash flow, which has forced it to fund the business through stock offerings. That's not a sustainable long-term strategy, but it's one investors and Wall Street have come to accept in the era of cheap money.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,